Drug Profile
Tesevatinib - Exelixis/Symphony Evolution
Alternative Names: KD-019; KD-020; Tesevatinib tosylate; XL-647Latest Information Update: 15 Mar 2022
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Exelixis; Kadmon Pharmaceuticals
- Class Amines; Antineoplastics; Cyclopentanes; Pyrroles; Quinazolines; Small molecules; Urologics
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Autosomal dominant polycystic kidney disease; Glioblastoma
- No development reported Autosomal recessive polycystic kidney disease; HER2 positive breast cancer; Liver cancer; Prostate cancer
Most Recent Events
- 25 Jan 2022 Kadmon Corporation completes a phase II trial in Autosomal-dominant polycystic kidney disease in USA (PO) (NCT03203642)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Autosomal-recessive-polycystic-kidney-disease(In children) in USA (PO, Suspension)
- 30 Apr 2020 Kadmon Pharmaceuticals completes a phase II trial in Glioblastoma (Recurrent, Second-line therapy or greater) in USA (PO) (NCT02844439)